Trump Health Funding Veto Board: What In-House Teams Must Do Now to Protect Research and Grant Contracts

What the Proposed Health Funding Board Actually Does

Reports suggest the Trump administration is considering a board with authority to review and veto federal health grants it deems ideologically misaligned, targeting research characterised as promoting diversity, equity and inclusion or related public-health frameworks. The mechanism is not yet codified in statute, but that is precisely the point: the legal ambiguity around how such a body would exercise its power creates contractual risk right now, before a single grant is cancelled.

For in-house counsel and compliance teams at universities, hospital systems, contract research organisations and non-profits, the question is not whether this is good or bad policy. The question is: which of our existing agreements are exposed, and what can we do about it?

The Contractual Exposure: Termination for Convenience and Grant Conditions

Almost every US federal grant or cooperative agreement incorporates standard FAR (Federal Acquisition Regulation) or Uniform Guidance provisions that permit the government to terminate funding for convenience, with limited recourse for the recipient beyond allowable costs incurred. The Guardian reported that the proposed board could veto initiatives before or during the funding period, meaning termination risk is not hypothetical. It is a foreseeable contractual event.

Organisations should map their agreements now. Key questions include: does the award incorporate a termination-for-convenience clause, and what costs are recoverable on termination? Are there milestones or deliverables that trigger liability to sub-recipients or academic partners if the prime award is pulled? Does the agreement contain representations about programme objectives that a new political definition of acceptable research could render non-compliant overnight?

DEI Clauses and Changing Compliance Obligations

The executive orders issued earlier in 2025 already placed DEI programme language under scrutiny across federal contracting. A health funding veto board would extend that scrutiny to grant-funded research, clinical programmes and public-health initiatives. Any agreement that contains language affirming commitments to health equity, minority-focused recruitment or gender-inclusive care could now attract review.

This creates a compliance obligation that did not exist two years ago: auditing existing grant language for terminology that post-dates the current administration's stated policy preferences. This is not a question of abandoning genuine programmatic goals. It is a question of understanding which contractual representations might be read as non-compliant by a reviewing body, and whether carve-out language or scope amendments are possible.

Supply Chain and Sub-Recipient Risk

Federal health funding rarely sits with a single organisation. Prime recipients pass money to sub-recipients, which may include community health organisations, overseas research partners or specialist laboratories. If a prime award is vetoed or terminated, the prime recipient is ordinarily contractually obligated to flow termination down to sub-awards, often with very short notice windows.

In-house teams should review every sub-award agreement for: the notice period on termination, indemnity provisions triggered by upstream government action, and whether force majeure or change-in-law clauses are broad enough to cover a policy-driven termination. Supply chain partners in sectors adjacent to health research, including life sciences, medical devices and diagnostics, should similarly assess whether their commercial contracts with federally funded customers contain adequate protections if that customer's funding evaporates.

What In-House Teams Should Renegotiate or Watch

The practical priority list for legal and compliance teams is as follows.

First, conduct a funded-programme audit. List every active federal health grant or contract, identify the termination provisions and calculate the financial exposure if each were stopped today.

Second, review sub-award flow-down obligations. Ensure your sub-recipients have received written notice that their awards are contingent on the prime award, and check whether your existing sub-award language gives you enough time to act if the government moves quickly.

Third, assess representations and certifications. Grants often require periodic certifications of compliance. If the definition of compliance is shifting, your next certification cycle is a legal risk event, not an administrative one.

Fourth, engage your insurers. Political risk and government-contract interruption policies vary widely. Confirm whether a policy-motivated grant termination is a covered event under your current coverage.

Fifth, watch the rulemaking closely. A board of this kind would likely need either a statutory basis or a formal executive order with published guidance. Each step in that process is an opportunity to submit comments, understand the precise scope of review and prepare contractual responses.

The Broader Signal for Global Health Contractors

Non-US organisations that receive NIH or CDC funding, or that partner with US-funded institutions, face the same exposure through their prime recipients. The signal is clear: US federal health funding is now a political variable, not a stable revenue line. Organisations that treat grant income as quasi-permanent will be caught off guard. Those that treat it as a contingent, regulatorily sensitive revenue stream and contract accordingly will be far better placed to respond, adapt and protect their sub-recipients and staff.

Adira's contract analysis layer can flag termination-for-convenience provisions, DEI-adjacent representations and flow-down obligations across a portfolio of agreements in a single review pass, giving teams the visibility to act before the next policy announcement changes the ground beneath them.